



CURRICULUM VITAE

PERSONAL INFORMATION	<p><b>Name and Surname:</b> Maria Concetta FARGNOLI  <b>Department:</b> Dermatology – Department of Biotechnological and Applied Clinical Sciences  <b>Address (work):</b> Via Vetoio – Coppito 2  <b>City:</b> L'Aquila <b>Postal code:</b> 67100  <b>Nation:</b> Italy  <b>E-mail address (work):</b> mariaconcetta.fagnoli@univaq.it</p>
CURRENT POSITION	<p>Full Professor – Dermatology and Venereology (SC 06/D4 – SSD MED/35), University of L'Aquila, Italy</p>
EDUCATION OTHER QUALIFICATIONS	<ul style="list-style-type: none"> <li>- 1986-1992. School of Medicine, University of Rome "Tor Vergata", Italy. Graduation thesis: "Psoriasis: pathogenesis and new insights into the role of growth factors (the EGF-TGF<math>\alpha</math> system)"</li> <li>- 1993-1997. Resident, Department of Dermatology, University of L'Aquila</li> <li>- July 1993 – September 1995. Postdoctoral fellow, Department of Dermatology, Yale University, Medical School, New Haven, Connecticut, USA. July 1993 – February 1994: laboratory of John Pawelek, Ph.D., research project on the effect of UVA and UVB on melanocyte cell cycle; March 1994-September 1995: laboratory of Ruth Halaban, Ph.D., research project on TCR signal transduction in cutaneous T cell lymphomas</li> <li>- February 1997 – August 1997. Guest resident, Department of Pathology, University of Munich, Germany. CNR (Consiglio Nazionale delle Ricerche) grant for an international collaborative research project on genetic analysis of melanoma susceptibility genes in familial melanoma patients</li> <li>- December 1997. Board certification in Dermatology and Venereology, University of L'Aquila</li> <li>- January 2002. Guest, laboratory of Molecular Biology Department of Dermatology, University of Graz, Austria. Collaborative project on germinal and somatic mutations of the <i>CDKN2A</i> gene in patients with multiple primary melanomas</li> <li>- March 2002 – July 2002. Guest, Department of Pathology, University of Munich, Germany. Collaborative project on <i>MC1R</i> genotype-phenotype correlation in Italian melanoma patients</li> <li>- December 2002 - September 2003. Training in Advanced Dermato-surgery, UO Dermatologia, Ospedale "M. Bufalini", Cesena, Italy</li> <li>- November 2015. Training in Confocal Laser Microscopy, Modena</li> <li>- September 2020. Course on Budgeting, performance and cost management: governing complex structures of Dermatology. SDA Bocconi School of Management, Milan</li> </ul>
ACADEMIC APPOINTMENTS	<ul style="list-style-type: none"> <li>- November 1999 - October 2006. Assistant Professor of Dermatology, University of L'Aquila</li> <li>- October 2006 - February 2017. Associate Professor of Dermatology,</li> </ul>



	<p>University of L'Aquila</p> <ul style="list-style-type: none"><li>- December 2013. National Scientific Qualification as Full Professor</li><li>- March 2017 - ongoing. Full Professor of Dermatology, University of L'Aquila</li></ul>
CLINIC APPOINTMENTS	<ul style="list-style-type: none"><li>- January 2004 - December 2014. Consultant, UOS Dermatology, Ospedale S. Salvatore, ASL-04 – L'Aquila</li><li>- January 2015 - ongoing. Chief, UOSD of Dermatology, Ospedale San Salvatore, ASL-01, Avezzano, Sulmona, L'Aquila</li><li>- August 2020 – ongoing. Coordinator of the Skin Cancer Tumor Board – ASL 1 Avezzano, Sulmona, L'Aquila, PO San Salvatore, L'Aquila</li></ul>
TEACHING EXPERIENCE	<ul style="list-style-type: none"><li>- School of Medicine</li><li>- Residency in Dermatology and Venereology, Plastic Surgery, Rheumatology, Occupational Medicine, Urology and Pediatrics</li><li>- Bachelor of Cosmetological Sciences and Technologies</li><li>- Bachelor of Nutrition</li><li>- Bachelor of Obstetrics</li><li>- Master of Medical and Pharmaceutical Biotechnologies</li><li>- Bachelor and Master of Nursing</li></ul>
RESEARCH ACTIVITIES	<p><u>Clinical research fields:</u></p> <ul style="list-style-type: none"><li>- Epidemiology of cutaneous melanoma and non-melanoma skin cancers</li><li>- Dermatoscopic and confocal microscopy characterization of pigmented and non-pigmented skin lesions</li><li>- Photodynamic therapy of skin cancers</li><li>- Italian and European guidelines for melanoma, basal and squamous cell carcinoma</li><li>- Evaluation of the efficacy, tolerability and pharmaco-economic aspects of topical and systemic medical therapies in nonmelanoma malignant skin neoplasms</li><li>- Evaluation of the efficacy and tolerability in real life of biological drugs and small molecules in psoriasis and atopic dermatitis</li><li>- Investigator for phase II, III, and IV clinical trials on new therapies for psoriasis and atopic dermatitis, non-melanoma skin cancers and cutaneous melanoma</li></ul> <p><u>Experimental research fields:</u></p> <ul style="list-style-type: none"><li>- Genetic susceptibility to cutaneous melanoma (familial, multiple and sporadic)</li><li>- Pigmentation genes (with special interest for the MC1R gene) in cutaneous malignant neoplasias</li><li>- Somatic mutation profiles in cutaneous primary melanoma and metastases</li><li>- Analysis of molecular pathways in the pathogenesis of basal cell carcinoma and squamous cell carcinoma</li></ul> <ul style="list-style-type: none"><li>- Member of the Advisory Committee of the international research project M-SKIP “MC1R, Skin cancer and Phenotypic characteristics”</li><li>- Member of the International Consortium “MelaNostrum” focusing on genetic epidemiology of melanoma in Southern Europe</li></ul>



<p>RESPONSIBILITY IN ACADEMIC ACTIVITIES</p>	<ul style="list-style-type: none"> <li>- 2013 - ongoing. Member of the Faculty Board of the PhD in Experimental Medicine (DOT13SR6G7), University of L'Aquila</li> <li>- February 2015 - ongoing. Director of the Interdepartmental Centre of Molecular Diagnostics and Advanced Therapies, University of L'Aquila</li> <li>- November 2015 - January 2017. Member and Vice-President of the Internal Review Board, University of L'Aquila</li> <li>- February 2017 – October 2019. President of the Internal Review Board, University of L'Aquila</li> <li>- July 2018 - ongoing. Member of the University's Senate (2018-2021), University of L'Aquila, Italy</li> <li>- November 2019 – ongoing. Member of the Internal Review Board, University of L'Aquila</li> </ul>
<p>EDITORIAL BOARD, EDITORIAL ACTIVITIES, SOCIETY MEMBERSHIP</p>	<ul style="list-style-type: none"> <li>- Referee ANVUR (National Agency for the Evaluation of Universities and Research Institutes) 2012 (VQR 2004-2010) and 2016 (VQR 2011-2014)</li> <li>- Board member of the “Giornale Italiano di Dermatologia e Venereologia” since 2012</li> <li>- Reviewer for international peer-reviewed journals (indexed by Scopus, ISI and PubMed)</li> </ul> <p><u>Society memberships:</u></p> <ul style="list-style-type: none"> <li>- Società Italiana di Dermatologia medica, chirurgica, estetica e di Malattie Sessualmente Trasmesse (SIDeMaST) Board Member (2016-2019) General Secretary (2016-2019) Group Coordinator – Experimental Research and Bioengineering in Dermatology (2016-2018) Chief of the Scientific Committee (2019-ongoing)</li> <li>- Board member of the Italian Multidisciplinary Group for Melanoma (GIPMe)</li> <li>- Board Member of the European Association of Dermato-Oncology (EADO)</li> <li>- European Dermatology Forum (EDF)</li> <li>- European Society for Dermatological Research (ESDR)</li> <li>- European Academy of Dermatology and venereology (EADV)</li> <li>- Associazione Italiana Diagnostica non Invasiva in Dermatologia (AIDNID)</li> <li>- Italian Melanoma Intergroup (IMI)</li> <li>- Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED)</li> </ul>
<p>SCIENTIFIC ACHIEVEMENTS BIBLIOMETRIC INDICATORS</p>	<p><b>Scopus Author ID:</b> 6701690192     <a href="http://orcid.org/000-0002-7249-2556">http://orcid.org/000-0002-7249-2556</a></p> <p>Hirsch (H) Index: 33 (Scopus)</p> <p>i10-Hirsch (H): 91 (Scopus)</p> <p>Normalized H-Index: 1.22 (Scopus)</p> <p>Total number of quotes: 3828 (Scopus)</p> <p>Median number of quotes by article 18.86 (Scopus)</p>
<p>SELECTED PUBLICATIONS</p>	<ul style="list-style-type: none"> <li>- Fargnoli MC, Esposito M, Dapavo P, Parodi A, Rossi M, Tiberio R, et al. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. J Eur Acad Dermatol Venereol. 2020 Sep 11. doi: 10.1111/jdv.16931.</li> </ul>



- Fagnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate- to-severe atopic dermatitis. *J Dermatolog Treat.* 2020 Jul 3:1-4. doi:10.1080/09546634.2020.1773379.
- Maturo MG, Rachakonda S, Heidenreich B, Pellegrini C, Srinivas N, Requena C, et al. Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma. *Sci Rep.* 2020 May 14;10(1):8005. doi:10.1038/s41598-020-65057-2.
- Chiricozzi A, Esposito M, Gisondi P, Valenti M, Gori N, Giovanardi G, et al. Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis. *Dermatology.* 2020;236(4):329-335. doi: 10.1159/000507246.
- Landi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, et al. *Nat Genet.* 2020 May;52(5):494-504. doi: 10.1038/s41588-020-0611-8.
- Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. *Eur J Cancer.* 2020 Mar;128:60-82. doi: 10.1016/j.ejca.2020.01.007.
- Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus- based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019. *Eur J Cancer.* 2020 Feb;126:141-158. doi: 10.1016/j.ejca.2019.11.014.
- Esposito M, Carubbi F, Giunta A, Alunno A, Giacomelli R, Fagnoli MC. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. *Expert Rev Clin Immunol.* 2020 Feb;16(2):119-128. doi:10.1080/1744666X.2020.1713754.
- Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019. *Eur J Cancer.* 2020 Feb;126:159-177. doi: 10.1016/j.ejca.2019.11.015.
- Pellegrini C, Cardelli L, Padova M, Nardo LD, Ciciarelli V, Rocco T, Cipolloni G, et al. Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases. *Acta Derm Venereol.* 2020 Jan 23;100(1):adv00040. doi: 10.2340/00015555-3382.
- Di Nardo L, Pellegrini C, Di Stefani A, Del Regno L, Sollena P, Piccerillo A, et al. Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. *J Eur Acad Dermatol Venereol.* 2020 May;34(5):932-941. doi: 10.1111/jdv.16098.
- Fagnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. *J Dermatolog Treat.* 2019 Oct 28:1-7. doi: 10.1080/09546634.2019.1682503.
- Peris K, Fagnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. *Eur J Cancer.* 2019 Sep;118:10-34. doi: 10.1016/j.ejca.2019.06.003.
- Gutiérrez García-Rodrigo C, Pellegrini C, Piccioni A, Tambone S, Fagnoli MC. Single versus two-treatment schedule of methyl aminolevulinate



- daylight photodynamic therapy for actinic keratosis of the face and scalp: An intra- patient randomized trial. *Photodiagnosis Photodyn Ther.* 2019 Sep;27:100-104. doi: 10.1016/j.pdpdt.2019.05.031.
- Moscarella E, Pellegrini C, Pampena R, Argenziano G, Manfredini M, Martorelli C, et al. Dermoscopic similarity is an independent predictor of BRAF mutational concordance in multiple melanomas. *Exp Dermatol.* 2019 Jul;28(7):829-835. doi: 10.1111/exd.13951.
  - Carubbi F, Fidanza R, Palmieri M, Ventura A, Tambone S, Cipriani P, et al. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. *J Dermatolog Treat.* 2020 Nov;31(7):692-697. doi: 10.1080/09546634.2019.1605143.
  - Ventura A, Pellegrini C, Cardelli L, Rocco T, Ciciarelli V, Peris K, Fargnoli MC. Telomeres and Telomerase in Cutaneous Squamous Cell Carcinoma. *Int J Mol Sci.* 2019 Mar 16;20(6):1333. doi: 10.3390/ijms20061333.
  - Pellegrini C, Botta F, Massi D, Martorelli C, Facchetti F, Gandini S, et al. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. *Lancet Child Adolesc Health.* 2019 May;3(5):332-342. doi: 10.1016/S2352-4642(19)30005-7.
  - Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. *J Immunother Cancer.* 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y.
  - Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, et al. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. *Oncologist.* 2019 Jun;24(6):e327-e337. doi: 10.1634/theoncologist.2018-0618.
  - Rossi M, Pellegrini C, Cardelli L, Ciciarelli V, Di Nardo L, Fargnoli MC. Familial Melanoma: Diagnostic and Management Implications. *Dermatol Pract Concept.* 2019 Jan 31;9(1):10-16. doi: 10.5826/dpc.0901a03.
  - Beretti F, Bertoni L, Farnetani F, Pellegrini C, Gorelli G, Cesinaro AM, et al. Melanoma types by in vivo reflectance confocal microscopy correlated with protein and molecular genetic alterations: A pilot study. *Exp Dermatol.* 2019 Mar;28(3):254-260. doi: 10.1111/exd.13877.
  - Mazzeo M, Saggini A, Rocco T, Fargnoli MC, Cerroni L. Syringotropic Lichen Planus: A Potential Histopathologic Mimicker of Syringotropic Mycosis Fungoides. *Am J Dermatopathol.* 2019 May;41(5):e50-e53. doi: 10.1097/DAD.0000000000001295.
  - Stratigos AJ, Fargnoli MC, De Nicolo A, Peris K, Puig S, Soura E, et al. MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the Melanostrum Consortium. *J Eur Acad Dermatol Venereol.* 2018 Dec;32(12):2134-2141. doi: 10.1111/jdv.15208.
  - Gu F, Chen TH, Pfeiffer RM, Fargnoli MC, Calista D, Ghorzo P, et al. Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. *Hum Mol Genet.* 2018 Dec 1;27(23):4145-4156. doi: 10.1093/hmg/ddy282.



- Farina AR, Cappabianca L, Ruggeri P, Gneo L, Pellegrini C, Fagnoli MC, et al. The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII. *J Exp Clin Cancer Res*. 2018 Jun 18;37(1):119. doi: 10.1186/s13046-018-0786-3.
- Cortellini A, Bersanelli M, Buti S, Gambale E, Atzori F, Zoratto F, et al. Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. *Immunotherapy*. 2018 Jun;10(8):643-655. doi: 10.2217/imt-2017-0167.
- Bassoli S, Pellegrini C, Longo C, Di Nardo L, Farnetani F, Cesinaro AM, et al. Clinical, dermoscopic, and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation. *Melanoma Res*. 2018 Apr;28(2):166-169. doi: 10.1097/CMR.0000000000000427.
- Fagnoli MC, Altomare G, Benati E, Borgia F, Broganelli P, Carbone A, et al. Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. *Eur J Dermatol*. 2017 Dec 1;27(6):599-608. English. doi: 10.1684/ejd.2017.3126.
- Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fagnoli MC. Understanding the Molecular Genetics of Basal Cell Carcinoma. *Int J Mol Sci*. 2017 Nov 22;18(11):2485. doi: 10.3390/ijms18112485
- Fagnoli MC, Ibbotson SH, Hunger RE, Rostain G, Gaastra MTW, Eibenschutz L, et al. Patient and physician satisfaction in an observational study with methyl aminolevulinate daylight photodynamic therapy in the treatment of multiple actinic keratoses of the face and scalp in six European countries. *J Eur Acad Dermatol Venereol*. 2018 May;32(5):757-762. doi: 10.1111/jdv.14691.
- Pellegrini C, Di Nardo L, Cipolloni G, Martorelli C, De Padova M, Antonini A, et al. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis. *J Mol Diagn*. 2018 Jan;20(1):110-122. doi: 10.1016/j.jmoldx.2017.10.002.
- Pellegrini C, Orlandi A, Costanza G, Di Stefani A, Piccioni A, Di Cesare A, et al. Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments. *PLoS One*. 2017 Aug 22;12(8):e0183415. doi: 10.1371/journal.pone.0183415.
- Pellegrini C, Maturo MG, Martorelli C, Suppa M, Antonini A, Kostaki D, Verna L, Landi MT, Peris K, Fagnoli MC. Characterization of melanoma susceptibility genes in high-risk patients from Central Italy. *Melanoma Res*. 2017 Jun;27(3):258-267. doi: 10.1097/CMR.0000000000000323.
- Caini S, Radice D, Tosti G, Spadola G, Coccorocchio E, Ferrucci PF, et al. Risk of second primary malignancies among 1537 melanoma patients and risk of second primary melanoma among 52 354 cancer patients in Northern Italy. *J Eur Acad Dermatol Venereol*. 2016 Sep;30(9):1491-6. doi: 10.1111/jdv.13645.
- Tagliabue E, Fagnoli MC, Gandini S, Maisonneuve P, Liu F, Kayser M, Nijsten T, et al. MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project. *Br J Cancer*. 2015 Jul



14;113(2):354-63. doi: 10.1038/bjc.2015.231.

- Carubbi F, Chimenti MS, Blasetti G, Cipriani P, Musto A, Fargnoli MC, et al. Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology/Rheumatology outpatient clinics. *J Eur Acad Dermatol Venereol.* 2015 Nov;29(11):2160-8. doi: 10.1111/jdv.13170.
- Fargnoli MC, Piccioni A, Neri L, Tambone S, Pellegrini C, Peris K. Conventional vs. daylight methyl aminolevulinic photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy. *J Eur Acad Dermatol Venereol.* 2015 Oct;29(10):1926-32. doi: 10.1111/jdv.13076.
- Suppa M, Micantonio T, Di Stefani A, Soyer HP, Chimenti S, Fargnoli MC, et al. Dermoscopic variability of basal cell carcinoma according to clinical type and anatomic location. *J Eur Acad Dermatol Venereol.* 2015 Sep;29(9):1732-41. doi: 10.1111/jdv.12980.
- Pasquali E, García-Borrón JC, Fargnoli MC, Gandini S, Maisonneuve P, Bagnardi V, et al. MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. *Int J Cancer.* 2015 Feb 1;136(3):618-31. doi: 10.1002/ijc.29018.
- Shi J, Yang XR, Ballew B, Rotunno M, Calista D, Fargnoli MC, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. *Nat Genet.* 2014 May;46(5):482-6. doi: 10.1038/ng.2941.
- Fargnoli MC, Sera F, Suppa M, Piccolo D, Landi MT, Chiarugi A, et al. Dermoscopic features of cutaneous melanoma are associated with clinical characteristics of patients and tumours and with MC1R genotype. *J Eur Acad Dermatol Venereol.* 2014 Dec;28(12):1768-75. doi: 10.1111/jdv.12411.
- Fargnoli MC, Suppa M, Micantonio T, Antonini A, Tambone S, Peris K. Dermoscopic features and follow-up changes of acral melanocytic naevi in childhood and adolescence. *Br J Dermatol.* 2014 Feb;170(2):374-81. doi: 10.1111/bjd.12667.
- Di Cesare A, Riitano A, Suppa M, Fidanza R, Zangrilli A, Esposito M, et al. Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity. *J Am Acad Dermatol.* 2013 Dec;69(6):947-53. doi: 10.1016/j.jaad.2013.08.017.
- Liang X, Pfeiffer RM, Li WQ, Brossard M, Burke LS, Wheeler W, et al. Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone families. *J Invest Dermatol.* 2014 Feb;134(2):481-487. doi: 10.1038/jid.2013.316.
- Iles MM, Law MH, Stacey SN, Han J, Fang S, Pfeiffer R, et al. A variant in FTO shows association with melanoma risk not due to BMI. *Nat Genet.* 2013 Apr;45(4):428-32, 432e1. doi: 10.1038/ng.2571.
- Fargnoli MC, Kostaki D, Piccioni A, Micantonio T, Peris K. Dermoscopy in the diagnosis and management of non-melanoma skin cancers. *Eur J Dermatol.* 2012 Jul-Aug;22(4):456-63. doi: 10.1684/ejd.2012.1727.
- Suppa M, Cazzaniga S, Fargnoli MC, Naldi L, Peris K. Knowledge, perceptions and behaviours about skin cancer and sun protection among



secondary school students from Central Italy. *J Eur Acad Dermatol Venereol.* 2013 May;27(5):571-9. doi: 10.1111/j.1468-3083.2012.04484.x.

- Di Cesare A, Sera F, Gulia A, Coletti G, Micantonio T, Fargnoli MC, et al. The spectrum of dermatoscopic patterns in blue nevi. *J Am Acad Dermatol.* 2012 Aug;67(2):199-205. doi: 10.1016/j.jaad.2011.08.018.
- Altobelli E, Marziliano C, Fargnoli MC, Petrocelli R, Maccarone M, Chimenti S, et al. Current psoriasis treatments in an Italian population and their association with socio-demographical and clinical features. *J Eur Acad Dermatol Venereol.* 2012 Aug;26(8):976-82. doi: 10.1111/j.1468-3083.2011.04196.x.
- Spica T, Fargnoli MC, Hetet G, Bertrand G, Formicone F, Descamps V, et al. EDNRB gene variants and melanoma risk in two southern European populations. *Clin Exp Dermatol.* 2011 Oct;36(7):782-7. doi: 10.1111/j.1365-2230.2011.04062.x.
- Fargnoli MC, Gandini S, Peris K, Maisonneuve P, Raimondi S. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. *Eur J Cancer.* 2010 May;46(8):1413-20. doi: 10.1016/j.ejca.2010.01.027.
- Altamura D, Menzies SW, Argenziano G, Zalaudek I, Soyer HP, Sera F, et al. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. *J Am Acad Dermatol.* 2010 Jan;62(1):67-75. doi: 10.1016/j.jaad.2009.05.035.
- Caini S, Gandini S, Sera F, Raimondi S, Fargnoli MC, Boniol M, et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. *Eur J Cancer.* 2009 Nov;45(17):3054-63. doi: 10.1016/j.ejca.2009.05.009.
- Di Lucca J, Guedj M, Lacapère JJ, Fargnoli MC, Bourillon A, Dieudé P, et al. Variants of the xeroderma pigmentosum variant gene (POLH) are associated with melanoma risk. *Eur J Cancer.* 2009 Dec;45(18):3228-36. doi: 10.1016/j.ejca.2009.04.034.
- Fargnoli MC, Pike K, Pfeiffer RM, Tsang S, Rozenblum E, Munroe D, et al. MC1R variants increase risk of melanomas harboring BRAF mutations. *J Invest Dermatol.* 2008 Oct;128(10):2485-90. doi: 10.1038/jid.2008.67.
- Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, Fargnoli MC. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. *Int J Cancer.* 2008 Jun 15;122(12):2753-60. doi: 10.1002/ijc.23396.
- Altamura D, Zalaudek I, Sera F, Argenziano G, Fargnoli MC, Rossiello L, et al. Dermoscopic changes in acral melanocytic nevi during digital follow-up. *Arch Dermatol.* 2007 Nov;143(11):1372-6. Doi: 10.1001/archderm.143.11.1372.
- Altobelli E, Petrocelli R, Marziliano C, Fargnoli MC, Maccarone M, Chimenti S, et al. Family history of psoriasis and age at disease onset in Italian patients with psoriasis. *Br J Dermatol.* 2007 Jun;156(6):1400-1. doi: 10.1111/j.1365-2133.2007.07906.x.
- Gerstenblith MR, Goldstein AM, Fargnoli MC, Peris K, Landi MT. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. *Hum Mutat.* 2007 May;28(5):495-505. doi:





10.1002/humu.20476.

- Piccolo D, Fargnoli MC, Ferrara G, Lozzi GP, Altamura D, Ventura T, et al. Hypoepiluminescence microscopy of pigmented skin lesions: new approach to improve recognition of dermoscopic structures. *Dermatol Surg.* 2006 Nov;32(11):1391-7. doi: 10.1111/j.1524 4725.2006.32311.x.
- Altamura D, Altobelli E, Micantonio T, Piccolo D, Fargnoli MC, Peris K. Dermoscopic patterns of acral melanocytic nevi and melanomas in a white population in central Italy. *Arch Dermatol.* 2006 Sep;142(9):1123-8. doi: 10.1001/archderm.142.9.1123.
- Peris K, Micantonio T, Fargnoli MC, Lozzi GP, Chimenti S. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. *J Am Acad Dermatol.* 2006 Aug;55(2):324-7. doi: 10.1016/j.jaad.2006.04.004.
- Fargnoli MC, Argenziano G, Zalaudek I, Peris K. High- and low-penetrance cutaneous melanoma susceptibility genes. *Expert Rev Anticancer Ther.* 2006 May;6(5):657-70. doi: 10.1586/14737140.6.5.657.
- Micantonio T, Fargnoli MC, Peris K. Usefulness of dermoscopy to monitor clinical efficacy of imiquimod treatment for lentigo maligna. *Arch Dermatol.* 2006 Apr;142(4):530-1. doi: 10.1001/archderm.142.4.530-b.
- Fargnoli MC, Altobelli E, Keller G, Chimenti S, Höfler H, Peris K. Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study. *Melanoma Res.* 2006 Apr;16(2):175-82. doi: 10.1097/01.cmr.0000198454.11580.b5.
- Fargnoli MC, Spica T, Sera F, Pellacani G, Chiarugi A, Seidenari S, et al. Re: MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. *J Natl Cancer Inst.* 2006 Jan 18;98(2):144-5; author reply 145-6. doi: 10.1093/jnci/djj025.
- Fargnoli MC, Frascione P. Images in clinical medicine. Acanthosis nigricans. *N Engl J Med.* 2005 Dec 29;353(26):2797. doi: 10.1056/NEJMicm050300.
- Peris K, Fargnoli MC, Pacifico A, Surrenti T, Stolz W, Wolf P, et al. CDKN2A and MC1R mutations in patients with sporadic multiple primary melanoma. *J Invest Dermatol.* 2004 May;122(5):1327-30. doi: 10.1111/j.0022-202X.2004.22532.x.
- Fargnoli MC, Piccolo D, Altobelli E, Formicone F, Chimenti S, Peris K. Constitutional and environmental risk factors for cutaneous melanoma in an Italian population. A case-control study. *Melanoma Res.* 2004 Apr;14(2):151-7. doi: 10.1097/00008390-200404000-00013.
- Fargnoli MC, Chimenti S, Keller G, Höfler H, Peris K. Identification of four novel melanocortin 1 receptor (MC1R) gene variants in a Mediterranean population. *Hum Mutat.* 2003 Jun;21(6):655. doi: 10.1002/humu.9150.
- Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. *N Engl J Med.* 1999 Dec 2;341(23):1767-8. doi: 10.1056/NEJM199912023412312.
- Fargnoli MC, Chimenti S, Keller G, Soyer HP, Dal Pozzo V, Höfler H, et al. CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds. *J Invest Dermatol.* 1998 Dec;111(6):1202-6. doi:



	<p>10.1046/j.1523-1747.1998.00412.x.</p> <ul style="list-style-type: none"><li>- Fagnoli MC, Edelson RL, Berger CL, Chimenti S, Couture C, Mustelin T, et al. Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70, Syk and membrane-associated Csk. <i>Leukemia</i>. 1997 Aug;11(8):1338-46. doi: 10.1038/sj.leu.2400745.</li><li>- Fagnoli MC, Orlow SJ, Semel-Concepcion J, Bologna JL. Clinicopathologic findings in the Bannayan-Riley-Ruvalcaba syndrome. <i>Arch Dermatol</i>. 1996 Oct;132(10):1214-8.</li><li>- Fagnoli MC, Bologna JL. Pentachrome vitiligo. <i>J Am Acad Dermatol</i>. 1995 Nov;33(5 Pt 2):853-6. doi: 10.1016/0190-9622(95)90422-0.</li></ul>
--	---

L'AQUILA, FEBRUARY 23, 2021